Morgan Ebert, Managing Editor

State repeals of nonmedical vaccine exemptions were linked to higher kindergarten vaccination rates, with minimal substitution toward medical exemptions.

The ACIP committee voted to pass both resolutions to update its recommendation on the hepatitis B vaccine for infants.

FDA approves expanded indication for MED-EL cochlear implants, allowing use in infants 7 months or older with bilateral SNHL and broadening pediatric eligibility.

Higher maternal vitamin D levels in pregnancy were associated with reduced odds of early childhood caries and lower dmft scores in offspring.

New US modeling study results find nirsevimab would avert the most infant RSV-LRTD events and hospitalizations compared with clesrovimab or RSVpreF maternal vaccination.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from November 2025.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

A phase 2b randomized trial found once-weekly navepegritide improved growth velocity, skeletal alignment, and physical functioning in children with achondroplasia.

A national poll shows many parents plan in-person Thanksgiving gatherings despite concerns about COVID-19 transmission and risks to high-risk relatives.

A prepandemic NHANES analysis found no significant differences in fruit, vegetable, or overall diet quality between WIC participants and eligible nonparticipants.

FDA approves Itvisma for patients 2 years and older with SMA, making it the first FDA-approved gene replacement therapy for this population.

Long-term data show sustained survival, immune recovery, and metabolic correction after lentiviral gene therapy for ADA-SCID, with no vector-related safety events.

National CPS data from 2012-2023 show declines in confirmed child maltreatment, but disparities remained, particularly among Black and female children.

FDA adds boxed warning to Elevidys and limits use to ambulatory DMD patients ≥4 years after reports of fatal acute liver failure in non-ambulatory patients.

Sub-analysis of ADORING trials shows VTAMA cream improved skin clearance, symptoms, and patient-reported outcomes in children aged 2-17.

Study of 99 pediatric patients found clinically significant CNVs in 30% of cases, supporting CMA as a first-tier test for developmental delay and ID.

FDA grants Breakthrough Device Designation to GeneDx genome and exome tests supporting diagnosis of life-threatening genetic disorders.

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network.

FDA approves first irritable bowel syndrome with constipation (IBS-C) treatment, linaclotide (Linzess), for children aged 7 years and older based on pediatric and adult trial data.

New 2025 AHA CPR guidelines update choking response, opioid overdose care, and pediatric training to improve survival outcomes.

FDA approves Kygevvi, the first therapy for thymidine kinase 2 deficiency, a rare mitochondrial disease marked by muscle weakness and early death.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from October 2025.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

A review highlights the benefits and risks of artificial sweeteners in glycemic control, insulin sensitivity, and gut microbiota balance.

FDA moves to remove unapproved ingestible fluoride drugs for children, citing microbiome and thyroid concerns.

In this Q&A, Abby Nerlinger, MD, breaks down how pediatricians can provide detailed care for children with military connections, based on a session presented at the 2025 AAP National Conference & Exhibition.

Unintentional marijuana ingestions in children under 5 rose over 1,000% in 7 years, with edibles and pandemic-related factors fueling the trend.

A study of 3,438 toddlers found slightly lower emotional and behavioral problems among children assessed during the COVID-19 pandemic.

IDWeek 2025 heads to Atlanta October 19–22 with cutting-edge sessions on AMR, AI, vaccines, HIV, pediatrics, and global health challenges.

FDA accepts MannKind’s sBLA for Afrezza in children and adolescents with diabetes.